Antibe Therapeutics increases previously announced non-brokered personal placement to up to $5.

Antibe Therapeutics increases previously announced non-brokered personal placement to up to $5,000,000 Antibe Therapeutics Inc. is very happy to announce, based on improved inbound demand, that the previously announced non-brokered private positioning has been increased to up to $5,000,000 on a single conditions and terms as announced in Antibe's news release dated March 21, 2014 cialisosterreich.com http://cialisosterreich.com . Related StoriesExpanded use for IntelliCap with further CE Mark for aspiration of fluidsLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E.

cipla

Spending on drug-resistant pathogens, including methicillin-resistant Staphylococcus aureus . When analyzed by Eli Perencevich of the University of Iowa and colleagues, the National Institute of Allergy and Infectious Diseases’ budget ‘awards approximately $69,000 in grant funds’ for every annual AIDS-related death in the U.S., and ‘for each death from MRSA, it awards $570,’ she writes. Related StoriesPeople puzzled about antibiotic resistance, shows WHO surveyVirginia Tech scientists discover new remedies to focus on antibiotic-resistant bacteriaUnlocking the genes behind antibiotic level of resistance: an interview with Professor RomesbergWith the WHO, the CDC, the Lancet, main medical societies, and two bills in Congress recognizing the need for drug-resistant pathogens, ‘[y]ou’d think, with those calls for attention, that combating antibiotic resistance would be a priority in the United States.